<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E90A72A-4A7B-4D2D-854B-4DE60094219A"><gtr:id>9E90A72A-4A7B-4D2D-854B-4DE60094219A</gtr:id><gtr:name>St James's University Hospital (Jimmy's)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60CF2338-C48E-4B28-859E-7ED00D89037E"><gtr:id>60CF2338-C48E-4B28-859E-7ED00D89037E</gtr:id><gtr:name>Merck Serono</gtr:name><gtr:address><gtr:line1>Via Einaudi 11</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6ACB6E20-4490-47F2-8F7C-B1AB4BB2E17C"><gtr:id>6ACB6E20-4490-47F2-8F7C-B1AB4BB2E17C</gtr:id><gtr:name>Scottish Poisons Information Bureau</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0517AC0E-EF12-4F19-A6DD-6406FF2123A2"><gtr:id>0517AC0E-EF12-4F19-A6DD-6406FF2123A2</gtr:id><gtr:name>Life Technologies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/990FEC22-C988-4943-AA62-01322D61942A"><gtr:id>990FEC22-C988-4943-AA62-01322D61942A</gtr:id><gtr:name>Medicines for Malaria Venture (MMV)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF3B349E-1F60-4EBC-9C0E-5EBACF4A7FC7"><gtr:id>BF3B349E-1F60-4EBC-9C0E-5EBACF4A7FC7</gtr:id><gtr:name>Research Medical Center, Kansas</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E90A72A-4A7B-4D2D-854B-4DE60094219A"><gtr:id>9E90A72A-4A7B-4D2D-854B-4DE60094219A</gtr:id><gtr:name>St James's University Hospital (Jimmy's)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60CF2338-C48E-4B28-859E-7ED00D89037E"><gtr:id>60CF2338-C48E-4B28-859E-7ED00D89037E</gtr:id><gtr:name>Merck Serono</gtr:name><gtr:address><gtr:line1>Via Einaudi 11</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6ACB6E20-4490-47F2-8F7C-B1AB4BB2E17C"><gtr:id>6ACB6E20-4490-47F2-8F7C-B1AB4BB2E17C</gtr:id><gtr:name>Scottish Poisons Information Bureau</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0517AC0E-EF12-4F19-A6DD-6406FF2123A2"><gtr:id>0517AC0E-EF12-4F19-A6DD-6406FF2123A2</gtr:id><gtr:name>Life Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/990FEC22-C988-4943-AA62-01322D61942A"><gtr:id>990FEC22-C988-4943-AA62-01322D61942A</gtr:id><gtr:name>Medicines for Malaria Venture (MMV)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF3B349E-1F60-4EBC-9C0E-5EBACF4A7FC7"><gtr:id>BF3B349E-1F60-4EBC-9C0E-5EBACF4A7FC7</gtr:id><gtr:name>Research Medical Center, Kansas</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/71087E01-D085-4094-80C8-484FCF5B21D1"><gtr:id>71087E01-D085-4094-80C8-484FCF5B21D1</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:surname>Park</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700654"><gtr:id>FBDE562C-B06A-479B-BBB5-7CD0FFBBAD41</gtr:id><gtr:title>CENTRE FOR DRUG SAFETY SCIENCE</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700654</gtr:grantReference><gtr:abstractText>It is estimated that adverse reactions to drugs constitute the 4th most common cause of death in the USA. In the UK, adverse drug reactions (ADRs) are a financial burden on the health services, a major cause of drug withdrawals for the pharmaceutical industry and a life-threatening experience for some patients. A recent survey indicated that 6.5% of hospital admissions were due to ADRs costing the Nation #466 million annually. With the increasing emphasis on polypharmacy and multidrug combination therapy, this situation is set to worsen. At the individual level, whilst many ADRs are relatively mild and self-limiting, in some cases ? in particular the allergic or hypersensitivity reactions ? they can result in permanent disability or fatality. Several recent high profile incidences of adverse drug reactions, for example the withdrawal of Vioxx (a COX2 inhibitor) because of heart attacks and the TGN1412 incident in Northwick Park in 6 healthy volunteers, have undermined confidence in existing preclinical testing procedures, and subsequent safety assessment in man. Despite this, our understanding of ADRs and the mechanisms underlying them are seriously deficient. ADRs are complex biological events which require broad-based expertise and meticulously conducted clinical studies to address. The Centre for Drug Safety Science will provide a unique infrastructure for studying the mechanisms of ADRs and will provide a focus for establishing the critical mass of expertise required to make a real impression on the incidence, prediction and management of such reactions, both within the health services and pharmaceutical industry. Our mission therefore is to create a world-class centre for the investigation of fundamental mechanisms by which adverse drug reactions which are important in our clinics and hospitals, with the overall aim of preventing such reactions through (a) better design of drugs, (b) identifying the factors by which ADRs only occur in some patients, and (c) develop better tests to identify these ADRs early before the reactions develop or become more severe. Another important effect of creating the Centre will be to increase scientific expertise in this area which is important for our healthcare system, regulatory agencies and pharmaceutical industry.</gtr:abstractText><gtr:technicalSummary>We propose to create a Centre for Drug Safety Science at the University of Liverpool, in collaboration with the University of Manchester, the MRC Toxicology Unit in Leicester, the Medicines for Healthcare products Regulatory Agency (MHRA) and Pharmaceutical Industry. This will provide a centre of excellence for research into drug safety, which is important because: (a) adverse reactions to drugs are common accounting for hospitalisations, visits to GPs and in some cases, patient deaths; (b) drugs continue to be withdrawn from the market because of safety concerns with adverse economic consequences and reduced expenditure on future R &amp;amp; D; (c) the number of new drugs coming onto the market has been poor over the last decade; and (d) the combination of drug withdrawals and lack of new drugs will adversely affect drug choice for patients.

Our mission in the Centre will be to enhance drug safety by developing a facility that will enable research that goes from the laboratory bench to the patient bedside (and vice versa) to identify, evaluate and understand the fundamental mechanisms of adverse drug reactions. We have a 20-year track record of research in this area. The Centre will allow us to consolidate and strengthen this expertise, and will have an unrivalled breadth of research ranging from fundamental cellular processes through animal physiology and pathology to modelling and human population studies, inter-linked in a real sense to add value to research into drug safety science right through from molecule to man. We believe that with Centre status we will be able to compete at the highest levels internationally in undertaking translational research in drug safety for the benefit of patients, the public, the industry and regulators. We have several objectives for the Centre: (a) enhance the safety of medicines; (b) provide new knowledge that informs the design and development of medicines in the future; (c) provide an environment for collaboration between scientists from Academia, NHS, Government and Industry; (d) facilitate training for safety scientists from both clinical and basic backgrounds; and (e) provide impartial advice to all relevant stakeholders.

Most importantly, we believe that a fundamental understanding of the mechanisms of adverse drug reactions will serve to inform the patient, the doctor and the medicinal chemist about the risk-benefit of new medicines and through this make drug therapy safer. This is the ultimate aim of our proposed Centre for Drug Safety Science.</gtr:technicalSummary><gtr:fund><gtr:end>2014-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4192100</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scottish Poisons Information Bureau</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Scottish Poisons Information Bureau</gtr:description><gtr:id>70D64963-434E-4FAB-BAF1-88A7733D2812</gtr:id><gtr:impact>Puiblication evaluating miR122 as a potential sensitive and specific biomarker of liver damage, PMID: 22045675. Recently reviewed in Faculty of 1000.
Additional high -impact publications in development.</gtr:impact><gtr:outcomeId>Sf9ext53YLH-1</gtr:outcomeId><gtr:partnerContribution>Provision of blood and urine samples from paracetamol overdose patients exhibiting liver damage</gtr:partnerContribution><gtr:piContribution>Evaluation of emerging and novel biomarkers of drug-induced liver (and kidney) injury</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis Institutes for BioMedical Research (NIBR)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Novartis collaboration</gtr:description><gtr:id>82A0CDBD-3AE1-4342-B6FF-A77A0964D63D</gtr:id><gtr:impact>None yet but in late stage negotiation for a formal project grant agreement</gtr:impact><gtr:outcomeId>CZg5EQ9WyjL-1</gtr:outcomeId><gtr:partnerContribution>Provision of lumiracoxib</gtr:partnerContribution><gtr:piContribution>Discussions on potential mechanisms of lumiracoxib toxicity</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca project grant</gtr:description><gtr:id>678337A2-5776-45A6-8A50-149D0E5DCA72</gtr:id><gtr:impact>Funding for 3 postdoctoral fellows</gtr:impact><gtr:outcomeId>ircFAZNagzY-1</gtr:outcomeId><gtr:partnerContribution>Access to equipment
Provision of drug compound
Evaluation of specific transgenic model system</gtr:partnerContribution><gtr:piContribution>Mechanistic investigation of ximelagatran-induced liver injury</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines for Malaria Venture (MMV)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>MMV research project - primaquine</gtr:description><gtr:id>44CFE4A4-1706-4EF0-983A-8223150AB4B0</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545cf58f54fd58.78188841-1</gtr:outcomeId><gtr:partnerContribution>Scientific input into project
Progress evaluation through monthly teleconferences</gtr:partnerContribution><gtr:piContribution>Scientific leadership and research activities from two postdoctoral fellows</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca Project Grant</gtr:description><gtr:id>8F9CED49-9038-4BDA-B6E4-2C5B6A33D80D</gtr:id><gtr:impact>Funding for 1 postdoctoral fellow</gtr:impact><gtr:outcomeId>q1xbd7k5EM9-1</gtr:outcomeId><gtr:partnerContribution>Provision of specifically synthesised chemicals for research project</gtr:partnerContribution><gtr:piContribution>Evaluation of the role of acyl glucuronides in liver toxicity</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Drug toxicity / Andrew Stachulski</gtr:description><gtr:id>9B6D62E2-8835-4CC4-B0CE-A0E5BDDF4EB5</gtr:id><gtr:impact>PMID: 17985860</gtr:impact><gtr:outcomeId>0C183B44F51-1</gtr:outcomeId><gtr:partnerContribution>Chemical expertise has made significant contributions to our understanding of protein biochemistry in adverse drug reactions. They have also been involved in synthesising reagents for protein quantification.</gtr:partnerContribution><gtr:piContribution>Ongoing long term collaboration to elucidate mechanisms of drug toxicity. We have provided expertise in protein mass spectrometry to complement their expertise in low molecular weight mass spectrometry.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>SAFE-T consortium formal collaborator</gtr:description><gtr:id>3B5139E7-3B65-4702-A459-122BCFCC39D2</gtr:id><gtr:impact>The collaboration has strengthened our links with Industry and has placed us in a good position to lead a bid for the 3rd Call IMI topic on drug induced liver injury</gtr:impact><gtr:outcomeId>foN69J5bX5w-1</gtr:outcomeId><gtr:partnerContribution>Progressing a number of biomarkers and assays that we have identified for formal validation and qualification for potential use in clinical studies</gtr:partnerContribution><gtr:piContribution>Intellectual leadership
Provision of novel biomarker techniques for potential use in clinical setting
Provision of clinical samples</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development GSK</gtr:department><gtr:description>GSK studentship 2013</gtr:description><gtr:id>2BE86BCC-B331-4591-8DE0-42E3399DB8B0</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>sG6rTtS7GEH-1</gtr:outcomeId><gtr:partnerContribution>Financial support
Placement of student at GSK research labs for at least 3 months of project</gtr:partnerContribution><gtr:piContribution>Scientific lead for project
Supervision of student</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca donation</gtr:description><gtr:id>BB3ADB0A-BF22-4426-B055-E6D450E7CD1F</gtr:id><gtr:impact>Biobank of HLA-typed healthy volunteer blood cells (described under Research Materials, G0700654B)</gtr:impact><gtr:outcomeId>LDij2nvhQhW-1</gtr:outcomeId><gtr:piContribution>development of clinical study to biobank blood samples from 400 healthy human volunteers</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines for Malaria Venture (MMV)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>MMV research grant</gtr:description><gtr:id>5E6CA878-32CE-4CD4-929E-AC3A0C930E30</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>JMjg4P8GFsk-1</gtr:outcomeId><gtr:partnerContribution>Financial
Scientific input into direction of project through monthly teleconferences</gtr:partnerContribution><gtr:piContribution>Scientific lead on project
Training and management of postdoctoral fellow</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Donation of a mass spectrometer</gtr:description><gtr:id>7C0AB700-72A7-4713-9781-92A6F5E8346F</gtr:id><gtr:impact>Significantly enhanced analytical capacity in CDSS that will help to support the substantial IMI-funded MIP-DILI project</gtr:impact><gtr:outcomeId>QQdQ7HNrbzV-1</gtr:outcomeId><gtr:partnerContribution>Donation of an ABSciex API4000 QTRAP mass spectromenter</gtr:partnerContribution><gtr:piContribution>Discussions on drug safety science strategies with individual Pfizer scientists and through CDSS workshops</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck Serono</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute of Drug Metabolism and Pharmacokinetics (DMPK)</gtr:department><gtr:description>Donation of a mass spectrometer</gtr:description><gtr:id>27D4CAD0-4804-4DC5-8386-8DC953F1E6B2</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>tmTHhJArerE-1</gtr:outcomeId><gtr:partnerContribution>Donation of an ABSciex API4000 mass spectrometer</gtr:partnerContribution><gtr:piContribution>Discussions on safety biomarker strategies with Merck scientists that should lead to formal project grant support</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Life Technologies</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Applied Biosystems</gtr:department><gtr:description>Mass Spectrometry Interactions</gtr:description><gtr:id>74D9AD40-F7E6-431E-9818-7CDF0D50EA4A</gtr:id><gtr:impact>19041286 16479536 Also produced technical notes on quantitation of proteins</gtr:impact><gtr:outcomeId>1170AD11899-1</gtr:outcomeId><gtr:partnerContribution>Technical expertise in advanced mass spectrometry and associated software.</gtr:partnerContribution><gtr:piContribution>Feedback on technical issues with mass spectrometry equipment. Guidance as to the future direction of software development.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Aventis</gtr:department><gtr:description>sanofi aventis project grant</gtr:description><gtr:id>3C2B3355-0FDF-495E-A7A2-CB832526620F</gtr:id><gtr:impact>Enhancing profile of CDSS within Industry. No publications to date.</gtr:impact><gtr:outcomeId>LY3T4YHbjKH-1</gtr:outcomeId><gtr:partnerContribution>Secondment of sanofi-aventis postdoctoral fellow to the CDSS for 3 months at start of project to facilitate expertise exchange</gtr:partnerContribution><gtr:piContribution>Evaluation of mechanisms of toxicity associated with existing and follow-on drugs</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Research Medical Center, Kansas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Hartmut Jaeschke</gtr:description><gtr:id>73D6F722-DD3C-4219-9870-A1738782ABE6</gtr:id><gtr:impact>One paper published (PMID 21396389) and another under revision.</gtr:impact><gtr:outcomeId>ScVkq6ZaEnD-1</gtr:outcomeId><gtr:partnerContribution>Collaboration to investigate mecahnisms of paracetamol-induced liver damage through the provision of patient samples.</gtr:partnerContribution><gtr:piContribution>Characterisation and quantitation of emerging and novel biomarkers of drug-induced liver injury</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St James's University Hospital (Jimmy's)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cystic Fibrosis Centre</gtr:department><gtr:description>Leeds Cystic Fibrosis Unit</gtr:description><gtr:id>7ABC46F4-B1F1-4005-836C-C543BA302E1E</gtr:id><gtr:impact>Publication -PMID 20481640</gtr:impact><gtr:outcomeId>Gj8ex7LoRXR-1</gtr:outcomeId><gtr:partnerContribution>Access to patient blood samples to further our mechanistic research into beta-lactam hypersensitivity</gtr:partnerContribution><gtr:piContribution>Bioanalysis of blood samples</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>JOINT BTS/BPS Joint Meeting, OCTOBER 2015 -EDINBURGH</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1871B6B7-904D-4384-A64D-AD869FC91D6C</gtr:id><gtr:impact>SPEECH DELIVERED : Drug safety pharmacogenomics :breaktrhoughs, challenges and opportunities - 
challenged thinking and new ways of working

additional requests / enquiries made in relation to CPT</gtr:impact><gtr:outcomeId>5613af36a9beb0.13420842</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>POLANI LECTURE February  2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D08A97D9-1121-4302-878D-96CC4D8A4B16</gtr:id><gtr:impact>POLANI LECTURE at Guys hospital makeup of the audience was geneticists, bioinformaticians, immunologists, dermatologists, clinicians, research workers (ranging from heads of groups to research students), and other interested parties. 

confirmed title Precision Medicine and Drug Safety: Opportunities and Challenges&amp;quot; followed by informal chat with Students</gtr:impact><gtr:outcomeId>56b872bc307525.07738218</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI CANCER CONFERENCE Liverpool 3rd November 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>84A8BD73-2B8B-4A47-B04F-EBBDC1215E59</gtr:id><gtr:impact>SYMPOSIUM &amp;quot;How integration of germline genetic information can improve diagnosis, treatment and prevention of cancer &amp;quot; 


REQUESTS MADE FOR FURTHER INFORMATION ON THE TOPIC AREA</gtr:impact><gtr:outcomeId>5639eac1c7eec8.26523746</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2015 MISG  New Technologies Forum on umbrella and basket protocols 27th October 2015.2FB.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>42667C14-8136-47EB-A515-F27A712CEFC7</gtr:id><gtr:impact>2015 MISG New Technologies Forum on umbrella and basket protocols 

raise awareness and understanding suppor best practice and produce recommendations for future regulatory guidance

assisted with the thinking in the proposals put forward</gtr:impact><gtr:outcomeId>562e0afdc2f652.02961864</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medicine in 1925 and in 2015: a symposium to mark the 90th Anniversary of the Postgraduate Medical Journal  1st october 2015 London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>569BF8A6-941A-4D6F-8735-259316F5C539</gtr:id><gtr:impact>presentation Progress in Personalised Medicines stimulated debate in the advancements of medicine from 1925 to present day.

request for further information in respect of topics covered in speech</gtr:impact><gtr:outcomeId>560d1e0a1faa83.39590821</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Local PROBUS presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8B9B8498-87CD-4833-BFE1-3A2F5499144D</gtr:id><gtr:impact>Presentation to 60 members of the Runcorn PROBUS group on the work of the CDSS

None</gtr:impact><gtr:outcomeId>VFH7D1Twn6R</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LHP / NICE CONFERENCE   liverpool 14.10.2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>817332EB-7A15-4703-A86B-F1E5B5BAF789</gtr:id><gtr:impact>dsicussion centred on How genetics can impact healthcare
- Increased availability of genetic testing and the future of primary care
- The importance of a free NHS in the era of genetic medicine
- Opportunities for personalised medicine


Increased knowledge and appetitle for Personalised medicine</gtr:impact><gtr:outcomeId>562e08723658d1.19442509</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture - university of Leeds 9th December  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>117ED93F-4EC6-47F9-8EB1-CF4F82BC3CEA</gtr:id><gtr:impact>lecture Stratified Medicine in 2015 - challenges and opportunities&amp;quot; provided students with opportunity to here the latest innovations in stratified medicine and challenge new ideas

a request for further lectures was made feedback generated much interest</gtr:impact><gtr:outcomeId>568523ffe408c9.21101921</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kuala Lumpar - Next generation pharmacogenomics March 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DBC5EF7A-C535-4403-9B00-B4E57CBE3234</gtr:id><gtr:impact>debate generated personalised medicine the challenging of developing the evidence base

students, academics and health professionals debated about such issues to inform discussion</gtr:impact><gtr:outcomeId>54f5a5de682b73.67547760</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personalised Medicine Conference in Oxford April 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>155E81A1-75B9-4DDA-81C0-9590B80A3160</gtr:id><gtr:impact>The conference is jointly organised by the Centre for Personalised Medicine in Oxford (a collaboration between the Wellcome Trust Centre for Human Genetics in Oxford and St Anne's College) and the PMWC 
 
A series of these conferences, organised by PMWC, have been held very successfully every year in Stanford. The Oxford conference will be the first of this series in Europe. 300 people, drawn from industry, academia, and the healthcare sector, to gather in Oxford across the three days for a conference focused on where personalised medicine fits in the clinic and on the practical applications of personalised medicine both now and in the near future.
 

 


insights and expertise in my role as NHS Chair of Pharmacogenetics provided a valuable addition to the conference</gtr:impact><gtr:outcomeId>552e79b5d92622.95232116</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DSRU's 8th Biennial Signal Detection Conference  June 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>856C94BD-3E27-46B4-A7E0-B7B1C7238C81</gtr:id><gtr:impact>TO ENGAGE WITH Pharmaceutical companies from Europe uk USA to discuss progress in The pharmacogenetic basis of adverse drug reactions

improved knowledge</gtr:impact><gtr:outcomeId>557ed965ae0569.07487826</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NWAC  - ALCHOHOL CONFERENCE Liverpool 20th November  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>42806266-4AA4-4E63-970C-8DDA8D749494</gtr:id><gtr:impact>Free conference to all medical, nursing, AHP, social care and third sector delegates, including students in relevant disciplines.
 
Discussions is again free to all medical, nursing, AHP, social care and third sector delegates, including students in relevant disciplines.
 
Discussions on the international, national and local perspectives will be supplemented by the showcasing of good practice examples and shared learning from practitioners across the country.
 
NWAC15 provided an unparalleled learning opportunity to exchange thoughts with peers, and build awareness of the range of approaches taken to reduce the harm caused to individuals and communities by alcohol abuse.
 

 


Participant advised that they left with insight which improved their own practice for patients and service users, as well as greater knowledge on how the national agenda is shaping up.</gtr:impact><gtr:outcomeId>564c4df925e1e3.31955770</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CPD lecture for MHRA    speech   the role of pharmacogenetics in drug safety 30th September 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DF381ADB-DC2A-404A-923D-F86173AB18EA</gtr:id><gtr:impact>the lectures are organised for MHRA assessor staff and are broadly based on the syllabus for physicians undertaking specialist training in pharmaceutical medicine. 
The audience usually comprises a range of medical, pharmaceutical/quality, non-clinical, scientific and statistical assessors. 


role of pharmacogenetics in drug safety presentation generated discussion and stimulation of ideas.</gtr:impact><gtr:outcomeId>560d1ce8ea3f11.42590241</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheshire WI presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0B4AD789-2B5C-4D0D-B74A-4421BBB9A889</gtr:id><gtr:impact>150 members of the Cheshire WIheard about the work of the CDSS in general and stem cell research in particular

None</gtr:impact><gtr:outcomeId>AUeRH8aRmDv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint ASCEPT-BPS Scientific Meeting May  2015  hong kong</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F2B90180-76E3-4BE0-A6EE-0276B78F766A</gtr:id><gtr:impact>symposium Phenotyping vs genotyping in HK slot of presentation 
presentation delivered &amp;quot; Has genotyping fulfilled its hopes to individualise drug therapy&amp;quot; and chared a session on Drug Discovery, Development And Evaluation

debate stimluated on the presentation delivered &amp;quot; Has genotyping fulfilled its hopes to individualise drug therapy&amp;quot; outlined next steps in this areas</gtr:impact><gtr:outcomeId>5555c1cdb13570.49299192</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://ascept-bps2015.com/programme-and-keynote-speakers-2/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Welsh Sixth Form Conference 2014 'Discovering Genomics' (Dan Hawcutt and Vincent Yip)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5AEED25A-75D0-4368-A39A-C18AC9550A19</gtr:id><gtr:impact>A presentation delivered to sixth form students entitled 'Pharmacogenomics: Personalising Medicine' was delivered to an audience of Sixth From students and the Wales Gene Park sixth form conference. The presentation sparked questions and discussion from the students.

Further invitations to take part in this kind of event.</gtr:impact><gtr:outcomeId>547de74c939155.11076130</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.walesgenepark.cardiff.ac.uk/2014/10/15/sixth-form-conferences-2014/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PSMN  WORKSHOP LONDON NOVEMBER 11TH 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9B1E3C4F-20DD-4F66-A6F0-3FB4F84C9EF2</gtr:id><gtr:impact>Work shop identified and highlighted progress and innovation in the filed of stratified medicine.

Ability to learn from industry and other collaborative partners on future direction of stratified medicine</gtr:impact><gtr:outcomeId>564b13324e9d64.09914873</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Making Sense of Drug Safety Science</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BDAE4CE8-BE67-4F37-BF52-A1CAC4E8C7FC</gtr:id><gtr:impact>Creation of a public awareness booklet called &amp;quot;Making Sense of Drug Safety Science&amp;quot; in collaboration with Sense About Science

Too early to say</gtr:impact><gtr:outcomeId>cduE6gHk5gi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.senseaboutscience.org/resources.php/138/making-sense-of-drug-safety-science</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IFCE CONFERENCE PARIS jUNE 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>49439D69-DA0D-45C5-A116-5AFACBF6E4C2</gtr:id><gtr:impact>New Developments in Pharmacogenetics&amp;quot; SPEECH to stimulate thinking

Stimualted thnking amongst those present</gtr:impact><gtr:outcomeId>55892215cc32d2.01620620</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC   Biannual Directors' Meeting.  18th November 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E8E0CD80-5A56-49C9-95CF-477970E1965F</gtr:id><gtr:impact>Information giving wIth colleagues associated with MRC

Continued discussion and dialogue on areas of research that affect/ impact and progress research initiatives</gtr:impact><gtr:outcomeId>564c3ed532a609.70187665</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trip to McLaren Woking 30th October 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F066A88F-47D7-4311-B12D-674A59A17423</gtr:id><gtr:impact>Trip to McLaren in Woking was to tease out potential collaboration and information in respect of public engagement and participation in activities to improve public Health,



potential collaboration and sharing of ideas for developing initiatives was explored.</gtr:impact><gtr:outcomeId>5639e8e2738af2.78836017</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKCCRF Manchester June 26th 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E79D3878-9734-4923-916A-C1219194F523</gtr:id><gtr:impact>Precision medicine in the ICU: The role of pharmacogenomics</gtr:impact><gtr:outcomeId>5589229f89d487.22980834</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ASCPT 2015 March 2015 New Orleans</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A7292A9E-4EBB-4D6D-92FD-01591F940A9B</gtr:id><gtr:impact>GREATER UNDERSTANDING OF PERSONALIZED MEDICINE USING GENOMEWIDE APPROACHES

INVITATION TO DISCUSS AT FUTURE EVENTS</gtr:impact><gtr:outcomeId>54f5789cacf4a3.99225685</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CDSS Worskshop  Gi toxicity December 1st 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4C6C1339-E222-4F27-B32B-C4511A271674</gtr:id><gtr:impact>Talk sparked discussion regarding governance /reporting of GI Toxicity

further information requested</gtr:impact><gtr:outcomeId>565ed85bb0e771.84316168</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Pharmaceutical Students' Association (BPSA), EASTERN CONFERENCE LINCOLN  7th NOVEMBER 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2DCFA2B7-4459-4501-8F0A-7E4E48832F9E</gtr:id><gtr:impact>Eastern Area Coordinator for the a student organisation representing over 14,500 pharmacy students across England and Wales. 

presentation delivered on topic of Personalised Medicine, encompassing two strands: pharmacogenetics (drug and dose selection based on individual genetic profiling) and personalising care through practice. 


The conference will host students from all four years of the MPharm course and from a range of different universities. We welcome a variety of methods of presenting the content to students and normal lecture room facilities are in place for you to present your topic.
Each conference normally attracts around 200 delegates at each conference. This is a fantastic opportunity for students to learn new skills and to gain knowledge related to the material that they may not encounter in depth at university. As the future of the pharmacy profession, it is vital for students to develop such knowledge in order to shape their careers. 


Sahred with students what pharmacists of tomorrow need to know in regards to this topic.</gtr:impact><gtr:outcomeId>5639ef16a1c2c9.40752100</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> Academy of Medical Sciences/Wellcome Trust meeting on 'Evaluating evidence in health', October 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1C050A91-ED17-40A8-9BA0-3394F9107220</gtr:id><gtr:impact>The workshop 1-day meeting for approximately 50 delegates, who will be senior representatives from academia, industry, the regulatory sector and the wider healthcare landscape. The workshop designed for discssion with the aim of ? Examine the strengths and limitations of evidence from different sources for determining risks (adverse events) and benefits (efficacy and effectiveness) of medicinal products.
? Explore how weaknesses in current approaches might be addressed, including discussion around evolving and novel trial designs, and methods of data collection, analysis and meta-analysis.
? Consider the future sources of data and how they might be used as evidence.
? Discuss how evidence can be effectively communicated to stakeholders, including patients, citizens, healthcare professionals and the media.
? Generate practical suggestions for enabling the better use of research evidence in healthcare decisions.

The outputs from this workshop will feed into the Academy's working group project on 'Methods of evaluating evidence' and work informing the Wellcome Trust's approach for accelerating the uptake of research into policy and practice.</gtr:impact><gtr:outcomeId>562e096f7d9660.90387476</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chief Scientific Officer Conference 1st March 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6D8A17D7-C891-4A8F-9474-876A7CB496FC</gtr:id><gtr:impact>The Vision For 2020 is aimed at senior leaders and healthcare scientists at all levels to start encouraging them to look to the future. healthcare scientists across all disciplines attended the event with the aim to show the depth and breadth of expertise that there is the event covered key changes and challenges in the healthcare and healthcare science landscape,
1. Science at the heart of the constitution
2. Healthcare Scientists delivering the change 
3. Emerging science 
4. Building the capacity and capability for change 
my contribution was bringing my expertise and knowledge to the theme of Personalised medicine</gtr:impact><gtr:outcomeId>56cef6384a5784.28236668</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIHR CRN National Coordinating Centre - Visit from Jonathan Sheffield and Team to Alder Hey 7th January 2016</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0FC73609-010B-4D18-9FF6-4F167964CA50</gtr:id><gtr:impact>Members of NIHR / CRN met with the Trust board and University to discuss strategic priorities and future plans in the area of Stratified/Personalised Medicine 


greater awareness and understanding of the theme of stratified and personalised medicine</gtr:impact><gtr:outcomeId>5694defddc9a58.53614238</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISSX Glasgow June  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B4EE972C-6665-4E3C-8556-F8D92C154BA8</gtr:id><gtr:impact>presentation on Implementation of Pharmacogenomics in Clinical Practice-focus on evidence-based medicine and cost-effectiveness&amp;quot;.

Greater understanding on th need for cost effectiveness for the need of Pharmacogenomics in Clinical Practice</gtr:impact><gtr:outcomeId>55891afea3ad98.85134722</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Farr Institute International Conference 2015, St Andrews, 26 - 28 August 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>79214A4D-756C-4894-BCE4-786F6D6523EB</gtr:id><gtr:impact>share thinking on the linkage with record darta and health informatics

researchers/ policy makers keen n the subject matter of topic of Linking Phenotype and Genotype</gtr:impact><gtr:outcomeId>55dc256e70ecd1.02411430</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academic Health Science Networks - Medicines Optimisation Event 26th November 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>346BC25F-ABCE-4910-B7D2-5FAB16EA65A4</gtr:id><gtr:impact>The day is to bring together AHSN teams working on MO to share progress on projects, to solve problems together and to build knowledge; in addition, the day will allow exchange of information with NHS E, ABPI and RPS. Through this we seek to build momentum for change, improve quality of each programme and ensure spread of improvement. There will be breakout sessions including one for those with Patient Safety Collaborative workstreams on medicines.

Safety - including thinking around the collaboratives
Outcomes - including implementing NICE TAs, building a case for use 'value based healthcare'
Patient Experience - including adherence</gtr:impact><gtr:outcomeId>56583cf4106cd3.15221414</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary open day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BED84634-0DA0-432D-B0A9-62C0078846CE</gtr:id><gtr:impact>An open evening to highlight MRC-funded reserach at the University of Liverpool. Highlights included the showing of a film about the Centre for Drug Safety Science and a keynote lecture from Lawrence McGinty

Local radio interview</gtr:impact><gtr:outcomeId>Lfw3oPdFaUv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIHR SENIOR investigator MEETING 3-4th November 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1559C8C8-F1E8-4A32-A61A-7807E2A1D3EF</gtr:id><gtr:impact>DISCUSSION ABOUT KEY ISSUES FACING NIHR AND ITS FUTURE DEVELOPMENT AND STRATEGY</gtr:impact><gtr:outcomeId>5639eba57546a7.21056431</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STRATEGY RETREAT &amp; BPS COUNCIL MEETING June 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D3E2DAB4-624F-494C-8644-C68F15027D00</gtr:id><gtr:impact>strategy going forward discussed

strategy for BPS AGREED</gtr:impact><gtr:outcomeId>557eda43c1f347.37445070</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FOCUS 2015, the National Meeting of the Association for Clinical Biochemistry and Laboratory Medicine,9-11th June 2015 in Cardiff</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4096CCD4-7DD0-49B4-BBF9-BD0008BC709E</gtr:id><gtr:impact>To assist thinking and understanding to medical and clinical scientist consultants in clinical biochemistry and trainees at various stages to . purpose of this symposium is to update on scientific principles and to highlight any areas likely to be of particular relevance to the hospital diagnostic laboratory.

Improved learning and knowledge from audience</gtr:impact><gtr:outcomeId>5577e63e236d97.95149925</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wilton Park dialogue 'The impact of the genomics revolution on global health - how can governments respond - March 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>70C08A6B-D190-4B98-860C-569CB9765714</gtr:id><gtr:impact>Invitation to attend a high-level Wilton Park dialogue organised in partnership with the Foreign and Commonwealth Office, the Science and Innovation Network (SIN) and Healthcare UK. The meeting focused on the potential of genomics and new precision medicines, including discussion on how governments can respond.</gtr:impact><gtr:outcomeId>56cef71f1d7881.00823892</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parliamentary Reception 14th december  2015 - BPS</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>36840B5B-B8BC-441C-8D2B-A63969ADCA84</gtr:id><gtr:impact>To discuss and promote CPT guidance in NHS

further request for attendance at NHS England meetings and with chief medial officers in Scotland, Ireland and Wales</gtr:impact><gtr:outcomeId>56852654f18a90.48579305</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>12th November 2015 - AHSN/ NHS ENGLAND EVENT LIVERPOOL</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E443DC4A-0E5E-4970-A6DF-910B011D5B42</gtr:id><gtr:impact>opportunity to shape personalised medicine in the NHS

NHS England Held three regional events with the Academic Health Science Networks (AHSNs) for representatives across their geographies to support the development of a strategy for a personalised medicine service for the NHS. The vision is that the strategy will embrace four overarching principles: prediction and prevention of disease; more precise diagnoses; targeted and personalised interventions; and a more participatory role for patients. this was achieved at the event with future plans made to implement the strategy</gtr:impact><gtr:outcomeId>564b14c71a5187.85179692</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCP advanced medicine conference Feb 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F46FF410-777D-445C-B97E-73F7D5369040</gtr:id><gtr:impact>talked on the topic of 'Important drug interactions' and chaired the session on pharmacology 
The event is a long-running and integral part of the annual RCP conferences programme t is designed to provide advanced medicine training to all physicians and to cover latest cutting-edge advances in clinical practice, underpinned by an improved understanding of the disease mechanism. The conference is one of the RCP's most high-level academic programmes and it's important to present the most cutting-edge scientific advances from across the specialties.</gtr:impact><gtr:outcomeId>56b87124da42d9.86970239</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PHARMARELA8 CONFERENCE  February 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E217B6A1-9C4E-4940-BD09-5ED3DC83C726</gtr:id><gtr:impact>debate on Genomics and therapeutics generated discussion on future direction of genomics and into impact in therapeutics</gtr:impact><gtr:outcomeId>56b86ce8b6aea0.12872981</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sense About Science topic specialist</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9B7214B1-26B3-4F34-B579-35065BE2B15A</gtr:id><gtr:impact>Providing scientifically correct statements for journalists on topics associated with drug safety and drug toxicity

Better links with Sense About Science</gtr:impact><gtr:outcomeId>AhdzqMwZuim</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>U-PGx Kick-off meeting Leiden Jan  2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EB5FC5A3-F8C2-4BA1-BF49-854EC6359E60</gtr:id><gtr:impact>Kick off Meeting for developing Systems pharmacology and Drug-drug interactions as part of a European consortium with other research institutes with a focus on ICT tools and the PGx infrastructure</gtr:impact><gtr:outcomeId>569f85e36b6345.62068005</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Voice of Young Science Forum 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>018429A2-0D5F-4E0D-A48A-11A34D587F64</gtr:id><gtr:impact>Approx 60 Degree and PhD students took part in forum on Science and the Media

Entered into a collaboration with Sense About Science to develop a &amp;quot;Making Sense of Drug Safety Science&amp;quot; pamphlet</gtr:impact><gtr:outcomeId>h1SzD97Bumf</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PHARMACOLOGY 2015 LONDON</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E1D269B1-2C00-4FB5-9A64-9E50DD37C708</gtr:id><gtr:impact>Generated discussion regarding CPT in NHS and the whole area of Pharmacology within UK</gtr:impact><gtr:outcomeId>568527163361c4.42956364</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>workshop facilitator</gtr:presentationType><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>86104</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Case award with AstraZeneca - 2012</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FC3D09E9-5CB0-4C49-A880-741E8D47718F</gtr:id><gtr:outcomeId>rfLRb9ot9fB</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>623743</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SC4SM Phase II Project Grant</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>Stem Cells for Safer Medicines (SC4SM)</gtr:fundingOrg><gtr:id>91805822-A462-4FAA-9708-A7E981FABDB7</gtr:id><gtr:outcomeId>5460e5754dbbd4.38430136</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3307918</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UKRMP Capital Equipment Call</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L012707/1</gtr:fundingRef><gtr:id>248FEBEC-C33C-482A-BB4D-162056B25A4C</gtr:id><gtr:outcomeId>tQ26VLeSxVv</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>148000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE award with GSK</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>4E818984-5439-4E03-87CA-BE36126CBBC3</gtr:id><gtr:outcomeId>QWUCUybdQqo0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4586388</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK Regenerative Medicine Platform</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K026739/1</gtr:fundingRef><gtr:id>FEDA40FB-4D2C-4CF7-90B7-0D34981A8647</gtr:id><gtr:outcomeId>MeFRorDrZXP</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>111147</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NWCR Project grant - Neil Kitteringham</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>North West Cancer Research (NWCR)</gtr:fundingOrg><gtr:id>E6047CB1-F074-48CE-9B6F-76B74E9AAD10</gtr:id><gtr:outcomeId>C47B8983F9B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>13000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RCUK China Office Travel Grant</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>Research Councils UK (RCUK)</gtr:fundingOrg><gtr:id>EC00A9B7-0110-47D7-81A6-FF9C7420FB2B</gtr:id><gtr:outcomeId>ZJpwx4fJu5c0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>107000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE award with AstraZeneca</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>F592E643-05F8-4A64-9EC6-E00577537876</gtr:id><gtr:outcomeId>NEBMJJgiKZP0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>82000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ITTP Studentship - 2010</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0A4AE987-D479-403F-BD41-758776E316AA</gtr:id><gtr:outcomeId>cnHcT88hG8e0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>282171</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust project grant</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>15A91719-F6FA-4D53-BAAE-2A1B155A5764</gtr:id><gtr:outcomeId>qib7QfC5BiB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Travelling Fellowship</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>535EABBA-18BE-43BF-B5EB-856FB8AFD548</gtr:id><gtr:outcomeId>M4Rv4EjsmZV0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>82000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ITTP Studentship -2010</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>579C64ED-A21A-4752-B55F-DB208478AA32</gtr:id><gtr:outcomeId>oorpkvohwnL0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ITTP Studentship - 2009</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A8AD4CE0-1683-4C34-BE88-917A54E6DF9A</gtr:id><gtr:outcomeId>dmbicARg8Fp0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>263394</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Project grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>2B56F6DB-5930-4B56-9CB7-191E43A27393</gtr:id><gtr:outcomeId>F5A5AD7343F0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>111147</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>North West Cancer Research project grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>North West Cancer Research (NWCR)</gtr:fundingOrg><gtr:fundingRef>CR986</gtr:fundingRef><gtr:id>BE3C6A5A-A4C6-4D27-A991-FD3AE254CA7E</gtr:id><gtr:outcomeId>BVybfbe9exa</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>179237</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PRIOMEDCHILD PAMPER consortium</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>674C16FF-53DD-4553-A378-F785533DB79D</gtr:id><gtr:outcomeId>QBBARni9zFT0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1209270</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SENSIT-IV Project grant</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>838451A0-C271-47AA-913C-B309750F5BC4</gtr:id><gtr:outcomeId>D43B7831CEA0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ITTP Studentship - 2011</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>467BB808-34D2-493A-BDA9-1EBC10EB6517</gtr:id><gtr:outcomeId>Eq9ynXdrZfE0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>82000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ITTP Studentship - 2010</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3A040151-CA30-415F-8C3D-FE7242A50874</gtr:id><gtr:outcomeId>qboAEe6yBaN0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ITTP Studentship - 2009</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5BE94D5B-6232-4FC4-B623-C6044981D3C1</gtr:id><gtr:outcomeId>Xkb7Y2yXuda0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3012000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Pharmacology Training Scheme</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C30EFC1A-E906-4CA9-9D40-E86E2851BFF1</gtr:id><gtr:outcomeId>HfgTHhneVEb0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>83712</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ITTP studentship - 2013</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0AB8F0B6-9A68-458B-8BB0-620AEB1011E7</gtr:id><gtr:outcomeId>5460e6ee439664.07186230</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>393062</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Commission FP7</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>15C5B50D-8624-42E8-BBC7-945DBC17E7D4</gtr:id><gtr:outcomeId>BAcLkx6JRNF</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This invention relates to methodology for detecting, assessing and/or diagnosing the presence of organ or tissue injury using blood-borne biomarkers CK18 and HMGB1</gtr:description><gtr:grantRef>G0700654</gtr:grantRef><gtr:id>7DBB9423-5B89-4D7D-BD78-0B6A4E284DE0</gtr:id><gtr:impact>Significant publications on the value of using these markers for predicting/detecting DILI in patients</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>Hm8X1eM8BbX</gtr:outcomeId><gtr:patentId>CA2766739</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>METHOD FOR THE DETECTION OF ORGAN OR TISSUE INJURY</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Methodology for detecting serum biomarkers that can be used in the detection, assessment and/or diagnosis of drug induced organ or tissue injury. The biomarkers comprise one or more of caspase-cleaved keratin 18, full-length keratin 18, hypo-acetylated HMGB1 and acetylated HMGB1.</gtr:description><gtr:grantRef>G0700654</gtr:grantRef><gtr:id>D64B17C9-8F52-4858-BB33-32A8B6E1D204</gtr:id><gtr:impact>Other patents granted: European patent number EP2449378; Japanese patent number 5721707</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c91b608c2f64.59627316</gtr:outcomeId><gtr:patentId>US8748109 B2</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Method for the detection of organ or tissue injury</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Re-appointment to Commission on Human Medicines for Professor Park</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>60F3ED44-1B50-49A0-8E1B-215345182468</gtr:id><gtr:outcomeId>SzGf3nrQh9N</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Personalised Medicine high level group- Round table discussion 17th November Sir Bruce Keogh</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E2A21F57-BDEE-48E6-8B71-1EC84D1E9278</gtr:id><gtr:outcomeId>564c3da860c506.50939872</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Re-appointment to Commision on Human Medicines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FD9317C3-4AB1-462F-9A99-C85D6336B6B3</gtr:id><gtr:outcomeId>hAE9PoXSSyX</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of SCAHT Scientific Advisory Board</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>BD39947D-0376-4E11-A88A-2420F9A56321</gtr:id><gtr:outcomeId>5460ef21899362.09596552</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A HLA-typed biobank of peripheral blood mononuclear cells for 400 healthy volunteers to a allow for a better mechanistic understanding of drug-induced hypersensitivity reactions</gtr:description><gtr:id>8EDD19CF-AB90-481C-8D85-802367E50CAD</gtr:id><gtr:impact>Defining a new paradigm for analysing the impact of the immune system on drug-induced organ injury</gtr:impact><gtr:outcomeId>gzZPUgUSd6B</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Healthy Volunteer HLA-typed Biobank</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Periperal blood mononuclear cells from multiple sclerosis patients treated with IFNbeta to allow us to assess the potential role of T regulatory cells in the generation of binding and neutralising antibodies</gtr:description><gtr:id>201D18CB-91C8-4340-A513-22E18B9423FD</gtr:id><gtr:impact>Pilot data has been used for a project grant application</gtr:impact><gtr:outcomeId>ppQyzzxnvz3</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Blood samples from IFNbeta treated MS patients</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Method for the absolute quanitification of proteins using stable isotope labels.</gtr:description><gtr:id>0AD3D10B-C926-46DC-ABD3-0A9E2FE515AA</gtr:id><gtr:impact>We have continued to develop and exploit this type of approach for the analysis of cancer progression, metastasis and drug toxicity.</gtr:impact><gtr:outcomeId>D5779752CB2</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Absolute quantification of protein</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CC3D7236-B3EB-467F-8601-5D7B55C74174</gtr:id><gtr:title>Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell function.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff945c76fcdbc4ec138b38b929320297"><gtr:id>ff945c76fcdbc4ec138b38b929320297</gtr:id><gtr:otherNames>Gibson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_540e154e1541969da</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D22359F9-B38F-47AC-A4BD-FA52796DF73E</gtr:id><gtr:title>Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/417ee48d075637d514eb7b978a734556"><gtr:id>417ee48d075637d514eb7b978a734556</gtr:id><gtr:otherNames>Lavergne SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>aZf3FEZrafQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>495D2155-9287-44C9-90D4-FFD5806AA938</gtr:id><gtr:title>Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice.</gtr:title><gtr:parentPublicationTitle>Toxicology and applied pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b35ce3a3b74ea6150b12eeb0a36050c"><gtr:id>3b35ce3a3b74ea6150b12eeb0a36050c</gtr:id><gtr:otherNames>Woolbright BL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0041-008X</gtr:issn><gtr:outcomeId>pm_540e154e154053b5b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62E8FAB9-80D9-4753-B476-37A4D30520DA</gtr:id><gtr:title>Cardiac Non-myocyte Cells Show Enhanced Pharmacological Function Suggestive of Contractile Maturity in Stem Cell Derived Cardiomyocyte Microtissues.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c35a6c3675f72acf743d0080b0484ad3"><gtr:id>c35a6c3675f72acf743d0080b0484ad3</gtr:id><gtr:otherNames>Ravenscroft SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>585d66b9741200.02446065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05045425-9EAC-427E-9EF8-CB352DB7E3DF</gtr:id><gtr:title>HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/369a7b3b1cfaf21e69bc0b37d13ae9d6"><gtr:id>369a7b3b1cfaf21e69bc0b37d13ae9d6</gtr:id><gtr:otherNames>Napolitano A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56d566617dbe66.98835575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B75E715A-E63B-4B8D-A3CE-927F2BC797B0</gtr:id><gtr:title>Validation of the isolation and quantification of kidney enriched miRNAs for use as biomarkers.</gtr:title><gtr:parentPublicationTitle>Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b341a4e384547c1e40e0a426fa293e54"><gtr:id>b341a4e384547c1e40e0a426fa293e54</gtr:id><gtr:otherNames>Sharkey JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1354-750X</gtr:issn><gtr:outcomeId>pm_16365_25_22356305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B08B619B-C2C0-445D-9D51-5634A251582A</gtr:id><gtr:title>&amp;quot;Danger&amp;quot; conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/417ee48d075637d514eb7b978a734556"><gtr:id>417ee48d075637d514eb7b978a734556</gtr:id><gtr:otherNames>Lavergne SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>bKyVKHwiPXP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A721F99-6A30-4DC1-B084-790F12FEE242</gtr:id><gtr:title>Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.</gtr:title><gtr:parentPublicationTitle>Toxicology and applied pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b35ce3a3b74ea6150b12eeb0a36050c"><gtr:id>3b35ce3a3b74ea6150b12eeb0a36050c</gtr:id><gtr:otherNames>Woolbright BL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0041-008X</gtr:issn><gtr:outcomeId>doi_55faa1aa1c85fda2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B980DE32-7DFB-4CB0-B1AC-39255AA57840</gtr:id><gtr:title>Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from Epoxide Metabolites of Carbamazepine in Patients.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b730eed49605806c487d7cf4dae71450"><gtr:id>b730eed49605806c487d7cf4dae71450</gtr:id><gtr:otherNames>Yip VLM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>5a2fd36c103211.22354313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D7C0BCA-F323-489D-9745-EB5636D115F1</gtr:id><gtr:title>How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43d2e516ca71ac3041d846a9709360d4"><gtr:id>43d2e516ca71ac3041d846a9709360d4</gtr:id><gtr:otherNames>Laverty H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>od8ZJngUkT9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A48EA494-20E7-4B6B-AB82-D9EC83BA3A0B</gtr:id><gtr:title>Haloarene derivatives of carbamazepine with reduced bioactivation liabilities: 2-monohalo and 2,8-dihalo derivatives.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87fd5aacb639d310e3b9e8efd6b29f36"><gtr:id>87fd5aacb639d310e3b9e8efd6b29f36</gtr:id><gtr:otherNames>Elliott EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_16365_25_23088585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4955BE6-CDC2-4120-A892-C178C968DCCD</gtr:id><gtr:title>Advances in the Pharmacogenomics of Adverse Drug Reactions.</gtr:title><gtr:parentPublicationTitle>Drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb81aa1d4a36387abc93c9841d80e769"><gtr:id>eb81aa1d4a36387abc93c9841d80e769</gtr:id><gtr:otherNames>Collins SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0114-5916</gtr:issn><gtr:outcomeId>568521ac8c4a45.78663892</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66EBF353-0F3D-4271-BF34-96BC9AC848EB</gtr:id><gtr:title>Progress in pharmacogenetics: consortiums and new strategies.</gtr:title><gtr:parentPublicationTitle>Drug metabolism and personalized therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b48fe6bdb409fdd002ad571691af05b9"><gtr:id>b48fe6bdb409fdd002ad571691af05b9</gtr:id><gtr:otherNames>Maro?as O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2363-8915</gtr:issn><gtr:outcomeId>56d45bb8ba6e07.43584306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8836EC6-F046-46AA-B8D0-B95565B8A525</gtr:id><gtr:title>Functional and toxicological consequences of metabolic bioactivation of methapyrilene via thiophene S-oxidation: Induction of cell defence, apoptosis and hepatic necrosis.</gtr:title><gtr:parentPublicationTitle>Toxicology and applied pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9d7587f4ad96c426ef860b78d68e47b"><gtr:id>b9d7587f4ad96c426ef860b78d68e47b</gtr:id><gtr:otherNames>Mercer AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0041-008X</gtr:issn><gtr:outcomeId>pm_16365_15_19523481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9095F54C-E3CE-464B-9B15-9331FD1A40BE</gtr:id><gtr:title>Genome-Based Infection Tracking Reveals Dynamics of Clostridium difficile Transmission and Disease Recurrence.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f6e2b589637133576bc99ec570b25b"><gtr:id>e8f6e2b589637133576bc99ec570b25b</gtr:id><gtr:otherNames>Kumar N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>568521ac65e706.67967817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>479ACC84-04B7-4D17-93DD-B3F69851C721</gtr:id><gtr:title>Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7c65909accd4a27eda463e8491418a9"><gtr:id>c7c65909accd4a27eda463e8491418a9</gtr:id><gtr:otherNames>Callan HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>CB57A47AA98</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9687EC39-8081-4A40-94F8-1BE000BD21E6</gtr:id><gtr:title>Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_16365_15_19782050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0112E0A-F0A5-426B-B4AE-A2999BD2766C</gtr:id><gtr:title>Activation of Flucloxacillin-Specific CD8+ T-Cells With the Potential to Promote Hepatocyte Cytotoxicity in a Mouse Model.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae4d1b720139535c8b1235a736c2e9cd"><gtr:id>ae4d1b720139535c8b1235a736c2e9cd</gtr:id><gtr:otherNames>Nattrass R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>5675e27846668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE503B73-AEA7-487F-9A44-91DD631B1A62</gtr:id><gtr:title>T cell responses to drugs and drug metabolites.</gtr:title><gtr:parentPublicationTitle>EXS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e22a2b47053bea6a036f06eeedd122ca"><gtr:id>e22a2b47053bea6a036f06eeedd122ca</gtr:id><gtr:otherNames>Earnshaw CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1023-294X</gtr:issn><gtr:outcomeId>545ce9cc1a4c83.85250251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC12731D-C519-41D9-A639-ACE0166F6CBC</gtr:id><gtr:title>Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b54d3a073b40a96717f37e2ec6921ce1"><gtr:id>b54d3a073b40a96717f37e2ec6921ce1</gtr:id><gtr:otherNames>Kitteringham NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn><gtr:outcomeId>VYpgmnRqe82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3918CBE-0DE2-4989-92FF-7B9C444AE52A</gtr:id><gtr:title>Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6df89b6324556c806bdd3836640b9da3"><gtr:id>6df89b6324556c806bdd3836640b9da3</gtr:id><gtr:otherNames>Copple IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>g3BzRrFHns8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C41B201C-3390-48E8-9F55-0A02E2507056</gtr:id><gtr:title>MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f8b5adafdd370252c7fc6d85d8b907"><gtr:id>e8f8b5adafdd370252c7fc6d85d8b907</gtr:id><gtr:otherNames>Kia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>doi_55f9849846407382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECA99A0A-BB5C-4B91-A875-E216D8CDEE21</gtr:id><gtr:title>Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study.</gtr:title><gtr:parentPublicationTitle>Cancer chemotherapy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106278a10a885219d4abc72f77d7635b"><gtr:id>106278a10a885219d4abc72f77d7635b</gtr:id><gtr:otherNames>Jones RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0344-5704</gtr:issn><gtr:outcomeId>pm_16365_25_23756919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25DB72CF-4C73-49DF-A5CA-932FF6396AC0</gtr:id><gtr:title>The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death.</gtr:title><gtr:parentPublicationTitle>Toxicology in vitro : an international journal published in association with BIBRA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/060ff5887c8f518c90aea1e8d2d518b1"><gtr:id>060ff5887c8f518c90aea1e8d2d518b1</gtr:id><gtr:otherNames>Kamalian L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0887-2333</gtr:issn><gtr:outcomeId>doi_55f984984615e71c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B52B6AFD-6F4F-4352-B1DF-56DB9C114217</gtr:id><gtr:title>Understanding the pathophysiological regulatory role of microRNAs in acute liver failure.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>545ce9cae4e763.97299175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF720162-BCBE-4C07-BDB0-186DD8E83078</gtr:id><gtr:title>The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2558bec17af68592fb9d20f274b1d03"><gtr:id>f2558bec17af68592fb9d20f274b1d03</gtr:id><gtr:otherNames>Harrill AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_16365_25_22739141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88FF086C-FB8E-4D88-90EC-EDD1605B9E2F</gtr:id><gtr:title>Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36c3f85de3f9f88c27d2230e55032c0c"><gtr:id>36c3f85de3f9f88c27d2230e55032c0c</gtr:id><gtr:otherNames>Elsheikh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>gzpSpANYm14</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA573077-AD9F-40BA-9704-AA1F210C60CC</gtr:id><gtr:title>Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d19dd5a51d1cf4ff43003c1c9e4cf808"><gtr:id>d19dd5a51d1cf4ff43003c1c9e4cf808</gtr:id><gtr:otherNames>Naisbitt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d5651572e037.31398763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F68EB22A-DA33-490C-9E7F-79B40F49A042</gtr:id><gtr:title>The development of in vitro culture methods to characterize primary T-cell responses to drugs.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2d9fa1a88f103697110ef54a94e06f0"><gtr:id>a2d9fa1a88f103697110ef54a94e06f0</gtr:id><gtr:otherNames>Faulkner L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>pm_16365_25_22331489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E65FC34-C7D4-45DE-BE9C-1A254540549C</gtr:id><gtr:title>Adaptation to acetaminophen exposure elicits major changes in expression and distribution of the hepatic proteome.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73e97dd03451d8d093a5e68f2993f3ff"><gtr:id>73e97dd03451d8d093a5e68f2993f3ff</gtr:id><gtr:otherNames>Eakins R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d56513992be2.65686607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>761E70FA-113A-4211-9EEF-4D5FD9268554</gtr:id><gtr:title>Safety pharmacology--current and emerging concepts.</gtr:title><gtr:parentPublicationTitle>Toxicology and applied pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df4ecc8e2688e61782a5d4920249e4d2"><gtr:id>df4ecc8e2688e61782a5d4920249e4d2</gtr:id><gtr:otherNames>Hamdam J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0041-008X</gtr:issn><gtr:outcomeId>pm_16365_25_23732082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41060FFB-78C8-436E-8DB3-8114CC6F5CCE</gtr:id><gtr:title>Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95beb9f08d58bc3e98da34110a6cbf70"><gtr:id>95beb9f08d58bc3e98da34110a6cbf70</gtr:id><gtr:otherNames>Venereau E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>pm_16365_25_22869893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31B5B38B-6AA0-4339-AEAB-8F8F1691CFDA</gtr:id><gtr:title>Are we closer to finding biomarkers for identifying acute drug-induced liver injury?</gtr:title><gtr:parentPublicationTitle>Biomarkers in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1752-0363</gtr:issn><gtr:outcomeId>pm_16365_25_23734798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54DE3854-8E1B-4E8E-8C2E-FE8972613A15</gtr:id><gtr:title>Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability.</gtr:title><gtr:parentPublicationTitle>Biology open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f33afcd1d7002fa259a663164003992d"><gtr:id>f33afcd1d7002fa259a663164003992d</gtr:id><gtr:otherNames>Wilkinson EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2046-6390</gtr:issn><gtr:outcomeId>5a2fd75f07e453.94749675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A2ED3AE-1F95-48DC-9A33-952104402445</gtr:id><gtr:title>Metabolic and chemical origins of cross-reactive immunological reactions to arylamine benzenesulfonamides: T-cell responses to hydroxylamine and nitroso derivatives.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a1048458e62f6588bdc7a9edefdcfc1"><gtr:id>3a1048458e62f6588bdc7a9edefdcfc1</gtr:id><gtr:otherNames>Castrejon JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>foJ52mNn4FG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C0A4616-4B11-493F-9AE4-D4D8D42B3FEF</gtr:id><gtr:title>Health-Economic Evaluation of Clostridium Difficile Infection (Cdi) And Epidemiology In England And Merseyside.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10f031052d961e069f64ecd0d6adbe4d"><gtr:id>10f031052d961e069f64ecd0d6adbe4d</gtr:id><gtr:otherNames>Nakamura CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>563c8b63144ce2.12789370</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F51F48A-386A-4286-885C-2626E8B29FD3</gtr:id><gtr:title>Plasma biomarkers to study mechanisms of liver injury in patients with hypoxic hepatitis.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/040b7205eaa6d00f1c608aa364140f9f"><gtr:id>040b7205eaa6d00f1c608aa364140f9f</gtr:id><gtr:otherNames>Weemhoff JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>585d3a246df238.58941539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>431872F0-3EB4-4BD8-AD47-B77DF6781E79</gtr:id><gtr:title>HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3bfa3b7807d59b84b48dfd2a1228e74"><gtr:id>e3bfa3b7807d59b84b48dfd2a1228e74</gtr:id><gtr:otherNames>Ogese MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>5675e1fd3b299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CF095AA-66C0-4152-9D68-BF77E29D6783</gtr:id><gtr:title>Childhood asthma exacerbations and the Arg16 ?2-receptor polymorphism: A&amp;nbsp;meta-analysis stratified by treatment.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3caab22aad47c553636b7980fd7e75a7"><gtr:id>3caab22aad47c553636b7980fd7e75a7</gtr:id><gtr:otherNames>Turner S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>569df42bab0377.35729203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB93354B-9612-493E-ABF2-B115DE110944</gtr:id><gtr:title>Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0657e0f67428a9fd42aaeab3b2c965da"><gtr:id>0657e0f67428a9fd42aaeab3b2c965da</gtr:id><gtr:otherNames>Dear JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>545ce9cc40f669.81602982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DAC7DF8-A818-4481-9AF1-5D347D660F3D</gtr:id><gtr:title>Stimulation of human T cells with sulfonamides and sulfonamide metabolites.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a1048458e62f6588bdc7a9edefdcfc1"><gtr:id>3a1048458e62f6588bdc7a9edefdcfc1</gtr:id><gtr:otherNames>Castrejon JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_16365_25_20159253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4B58B36-9CBA-424D-B164-597D84BADA9E</gtr:id><gtr:title>Explanation for HLA-B*57:01-linked immune-mediated abacavir-induced hypersensitivity.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5866bff6b7be8772b0bc13c9117fba67"><gtr:id>5866bff6b7be8772b0bc13c9117fba67</gtr:id><gtr:otherNames>Alfirevic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>pm_16365_25_23148633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CA06B54-D333-4A99-88FD-891DE0A65C84</gtr:id><gtr:title>Mechanistic biomarkers in acute liver injury: are we there yet?</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebe0fbfc74a075ba19a07c4460d865a7"><gtr:id>ebe0fbfc74a075ba19a07c4460d865a7</gtr:id><gtr:otherNames>Adebayo D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>doi_55f98498460caa11</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98FE693B-9EFD-48BA-8091-D91DA5066E88</gtr:id><gtr:title>Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/733c748369e0b187e9271725febc9547"><gtr:id>733c748369e0b187e9271725febc9547</gtr:id><gtr:otherNames>Hawcutt DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>5a3259ab397479.81842684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97C98A7F-1072-46AE-8566-74775A40F7E2</gtr:id><gtr:title>Circulating microRNAs as potential markers of human drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebe471943ec9fecbf4f5c3cf016c41d9"><gtr:id>ebe471943ec9fecbf4f5c3cf016c41d9</gtr:id><gtr:otherNames>Starkey Lewis PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>doi_55f9849845f8b610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22037B42-531A-44DF-A092-B55FBC2A56F4</gtr:id><gtr:title>Idiosyncratic adverse drug reactions: current concepts.</gtr:title><gtr:parentPublicationTitle>Pharmacological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/091907538141778dc67f0f37bac0234e"><gtr:id>091907538141778dc67f0f37bac0234e</gtr:id><gtr:otherNames>Uetrecht J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0031-6997</gtr:issn><gtr:outcomeId>pm_16365_25_23476052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5B5EA27-0DCC-4903-BAD1-1207E7C4417D</gtr:id><gtr:title>MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans.</gtr:title><gtr:parentPublicationTitle>Expert review of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/297bb4e95159a0879f4fcf0dda6d0cc2"><gtr:id>297bb4e95159a0879f4fcf0dda6d0cc2</gtr:id><gtr:otherNames>Hornby RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1751-2433</gtr:issn><gtr:outcomeId>545ce9cbcab267.48594859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>304C9423-A098-4F8A-AAB1-9E30C4C774E9</gtr:id><gtr:title>Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2436b505841d1fe76d0f50b168e3aa3f"><gtr:id>2436b505841d1fe76d0f50b168e3aa3f</gtr:id><gtr:otherNames>McWilliam SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16365_25_22937100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48EE27F3-2F8B-41EF-AA67-D14BC8902034</gtr:id><gtr:title>Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/624bbc02186f52ed82f477482cc2f056"><gtr:id>624bbc02186f52ed82f477482cc2f056</gtr:id><gtr:otherNames>Kim SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5675e4faa48f4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80EE44E9-92D6-42F3-924B-FF056766FBB5</gtr:id><gtr:title>Achieving the World Health Organization's vision for clinical pharmacology.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5626445be489cc30af426175486aac60"><gtr:id>5626445be489cc30af426175486aac60</gtr:id><gtr:otherNames>Martin JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>5620d0b5953ec7.04466506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B27EBA49-B4C3-4BDF-A959-C3075FEB95B4</gtr:id><gtr:title>Assessing the safety of stem cell therapeutics.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b32a981511d90997eefade788477b715"><gtr:id>b32a981511d90997eefade788477b715</gtr:id><gtr:otherNames>Goldring CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>Y6QKrjjk1DU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3ABA6D03-E372-4281-BC8D-E1714F61BBA2</gtr:id><gtr:title>Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5624e74948be84.50514683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CED812B6-0C7F-4E21-9EA0-17EE08F6EA6B</gtr:id><gtr:title>Managing the challenge of chemically reactive metabolites in drug development.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b41e0011b97cdcc271473f769dc49182"><gtr:id>b41e0011b97cdcc271473f769dc49182</gtr:id><gtr:otherNames>Park BK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>G4USDhekLkN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80075139-6A2D-4692-A04A-A16CE536B7C6</gtr:id><gtr:title>A mechanistic investigation into the irreversible protein binding and antigenicity of p-phenylenediamine.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/179964427664d560060191a8a6c31cf4"><gtr:id>179964427664d560060191a8a6c31cf4</gtr:id><gtr:otherNames>Jenkinson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>eSiQ6Ee8A7f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9D07A13-4E44-40FF-AEE9-C21A32D6A291</gtr:id><gtr:title>Novel role of PKR in inflammasome activation and HMGB1 release.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bdc2102df5bf859e025d454b10d0eeb"><gtr:id>7bdc2102df5bf859e025d454b10d0eeb</gtr:id><gtr:otherNames>Lu B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_16365_25_22801494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>242E8CF2-D3BB-4367-BA66-5FF6F6C048EA</gtr:id><gtr:title>Trimethoprim stimulates T-cells through metabolism-dependent and -independent pathways.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36fde6859daf9489006d8cddab8dcdbe"><gtr:id>36fde6859daf9489006d8cddab8dcdbe</gtr:id><gtr:otherNames>El-Ghaiesh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>pm_16365_25_21491947</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FC4CE01-253F-4090-93A9-0FF835261178</gtr:id><gtr:title>No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2d9fa1a88f103697110ef54a94e06f0"><gtr:id>a2d9fa1a88f103697110ef54a94e06f0</gtr:id><gtr:otherNames>Faulkner L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>585d3613c4a495.49998631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAA500F2-4733-4E17-928D-724C2BD31063</gtr:id><gtr:title>HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc09024bc44f267fc9eac5bed53d2bf8"><gtr:id>dc09024bc44f267fc9eac5bed53d2bf8</gtr:id><gtr:otherNames>Cheung CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>565839ea6564e5.80560057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D12BD2B3-C953-4674-A85A-274EF3534BDB</gtr:id><gtr:title>Quantification of urinary mevalonic acid as a biomarker of HMG-CoA reductase activity by a novel translational LC-MS/MS method.</gtr:title><gtr:parentPublicationTitle>Bioanalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7c3fe5d8ec9f343325d0281d8282f13"><gtr:id>c7c3fe5d8ec9f343325d0281d8282f13</gtr:id><gtr:otherNames>Rodrigues AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1757-6180</gtr:issn><gtr:outcomeId>545ce9cb85b6b7.01807616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6771DA34-7A9E-4A26-8F46-8ECFC1E8783F</gtr:id><gtr:title>Detection of drug-responsive B lymphocytes and antidrug IgG in patients with ?-lactam hypersensitivity.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36397f502012809ce2e57a15f28eec2c"><gtr:id>36397f502012809ce2e57a15f28eec2c</gtr:id><gtr:otherNames>Amali MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>58c7bad4e4ea87.75324308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD02B0E8-DA79-4533-B4F7-A1BD42B00337</gtr:id><gtr:title>Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cc39cb9af6b651fa3ac9be2f82e9caa"><gtr:id>7cc39cb9af6b651fa3ac9be2f82e9caa</gtr:id><gtr:otherNames>Farrell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_16365_25_23672781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DC379B1-845D-401E-8EE1-7E94FB11294C</gtr:id><gtr:title>Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bc703f57d1695f3c7bec8e79c7a5470"><gtr:id>4bc703f57d1695f3c7bec8e79c7a5470</gtr:id><gtr:otherNames>Garner CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>5675defa29585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>607EDDF3-78AD-4033-895A-EDD47401E9D7</gtr:id><gtr:title>Measurement of CD4+ and CD8+ T-lymphocyte cytokine secretion and gene expression changes in p-phenylenediamine allergic patients and tolerant individuals.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa3cdfa96a65cfa8338c079f4455c193"><gtr:id>aa3cdfa96a65cfa8338c079f4455c193</gtr:id><gtr:otherNames>Coulter EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>KdM9Esoqjhq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59E0609E-6FC3-4FB8-8AFC-D06141F28320</gtr:id><gtr:title>Monocyte unresponsiveness and impaired IL1?, TNFa and IL7 production are associated with a poor outcome in Malawian adults with pulmonary tuberculosis.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4d57e7ccac0cf1e7cbdb915c51fa748"><gtr:id>e4d57e7ccac0cf1e7cbdb915c51fa748</gtr:id><gtr:otherNames>Waitt CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>564b102d6271d2.67121999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88A1BB98-2586-45BB-87C8-DAE875831BD0</gtr:id><gtr:title>Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_16365_25_23390034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FB1CA64-7FBD-4D48-970A-ABDC44ADE520</gtr:id><gtr:title>The potential of cytokines as safety biomarkers for drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>European journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41d13e6256fcf30bccaf5e05656e7cb"><gtr:id>a41d13e6256fcf30bccaf5e05656e7cb</gtr:id><gtr:otherNames>Laverty HG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0031-6970</gtr:issn><gtr:outcomeId>pm_16365_25_20694460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAFCC4CF-C95D-42EA-AB7D-CFC7741779C4</gtr:id><gtr:title>Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d53a3afd301c96535e58f4eb19ac9f4c"><gtr:id>d53a3afd301c96535e58f4eb19ac9f4c</gtr:id><gtr:otherNames>Heslop JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn><gtr:outcomeId>doi_55f98498465b34c0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6E7E976-54A9-4F12-AC05-0EFE106480FA</gtr:id><gtr:title>Chemical tuning enhances both potency toward nrf2 and in vitro therapeutic index of triterpenoids.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6df89b6324556c806bdd3836640b9da3"><gtr:id>6df89b6324556c806bdd3836640b9da3</gtr:id><gtr:otherNames>Copple IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>545ce9cba74936.77592277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2164CC3E-6BE4-4550-B7F1-F56510D94CFF</gtr:id><gtr:title>The importance of hapten-protein complex formation in the development of drug allergy.</gtr:title><gtr:parentPublicationTitle>Current opinion in allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2d9fa1a88f103697110ef54a94e06f0"><gtr:id>a2d9fa1a88f103697110ef54a94e06f0</gtr:id><gtr:otherNames>Faulkner L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1473-6322</gtr:issn><gtr:outcomeId>545ce9cb3a18a4.40732007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0EBD8D0-2582-4BA6-BE05-2BDD57808F96</gtr:id><gtr:title>Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1).</gtr:title><gtr:parentPublicationTitle>Molecular medicine (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1076-1551</gtr:issn><gtr:outcomeId>pm_16365_25_22105604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADC116FB-983C-4435-8C3A-2B962BFEB56E</gtr:id><gtr:title>Examination of the cytotoxic and embryotoxic potential and underlying mechanisms of next-generation synthetic trioxolane and tetraoxane antimalarials.</gtr:title><gtr:parentPublicationTitle>Molecular medicine (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6df89b6324556c806bdd3836640b9da3"><gtr:id>6df89b6324556c806bdd3836640b9da3</gtr:id><gtr:otherNames>Copple IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1076-1551</gtr:issn><gtr:outcomeId>pm_16365_25_22669474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>372429CA-A1CC-4ADC-8DA1-38C5C292BAF1</gtr:id><gtr:title>Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ee0548ea9f20fc8585fef80f1dc5f05"><gtr:id>7ee0548ea9f20fc8585fef80f1dc5f05</gtr:id><gtr:otherNames>Thulin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>doi_55f98498464942e0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B358E857-3AF3-4196-91EA-B1D556545BC2</gtr:id><gtr:title>Comparison of the reactivity of antimalarial 1,2,4,5-tetraoxanes with 1,2,4-trioxolanes in the presence of ferrous iron salts, heme, and ferrous iron salts/phosphatidylcholine.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0537da2d024b2b20216b11162d2aaf6"><gtr:id>e0537da2d024b2b20216b11162d2aaf6</gtr:id><gtr:otherNames>Bousejra-El Garah F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>kGBr6rJGXsV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41E61565-ABF3-444C-96DF-DC976B33EA58</gtr:id><gtr:title>In Vitro Priming of Nai?ve T-cells with p-Phenylenediamine and Bandrowski's Base.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff945c76fcdbc4ec138b38b929320297"><gtr:id>ff945c76fcdbc4ec138b38b929320297</gtr:id><gtr:otherNames>Gibson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>585d5763928f49.39237694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CBCFF40-DFB6-43A3-B010-6B9AD22FAC07</gtr:id><gtr:title>Direct evidence for the formation of diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillenic acid in patients.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b7b1dadfe0840b56df4eb942edf8fc5"><gtr:id>9b7b1dadfe0840b56df4eb942edf8fc5</gtr:id><gtr:otherNames>Meng X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>eUs4TeVsEYB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E205D2BA-4B81-45B3-85D9-036733EFAFBE</gtr:id><gtr:title>Characterization of p-phenylenediamine-albumin binding sites and T-cell responses to hapten-modified protein.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/179964427664d560060191a8a6c31cf4"><gtr:id>179964427664d560060191a8a6c31cf4</gtr:id><gtr:otherNames>Jenkinson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>pm_16365_15_19710686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FB3FAF3-25EF-428A-8FFA-57AE01EA057D</gtr:id><gtr:title>Immune pathomechanism of drug hypersensitivity reactions.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae7fd4ef1a09669ba5de87bf1665239"><gtr:id>fae7fd4ef1a09669ba5de87bf1665239</gtr:id><gtr:otherNames>Pichler WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_16365_25_21354503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10279A38-B524-4AEB-B14D-7FF5F3A67FDC</gtr:id><gtr:title>Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e93532ef784604c2bb84d42b826c1bdb"><gtr:id>e93532ef784604c2bb84d42b826c1bdb</gtr:id><gtr:otherNames>Hammond TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>pm_540e154e15434c6d4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EB90A78-9706-4E39-8F8E-A8124E1B4F4F</gtr:id><gtr:title>Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba38be15f4dc6a28fe429b8b91730b43"><gtr:id>ba38be15f4dc6a28fe429b8b91730b43</gtr:id><gtr:otherNames>Olayanju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn><gtr:outcomeId>doi_55f984984602d9a2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6745E7A-B3C9-4695-BF1D-0CF2E88E3C0B</gtr:id><gtr:title>HLA restriction of carbamazepine-specific T-Cell clones from an HLA-A*31:01-positive hypersensitive patient.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44047f3f2103c7efda9f3589ed5589c3"><gtr:id>44047f3f2103c7efda9f3589ed5589c3</gtr:id><gtr:otherNames>Lichtenfels M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>pm_540e154e1540e421d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2926A142-F832-4F79-B2DC-68F6034DCEDE</gtr:id><gtr:title>Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity.</gtr:title><gtr:parentPublicationTitle>Chemico-biological interactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b41e0011b97cdcc271473f769dc49182"><gtr:id>b41e0011b97cdcc271473f769dc49182</gtr:id><gtr:otherNames>Park BK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-2797</gtr:issn><gtr:outcomeId>pm_16365_25_20846520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34214246-594E-46B8-8134-298CDDA170CD</gtr:id><gtr:title>Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b7b1dadfe0840b56df4eb942edf8fc5"><gtr:id>9b7b1dadfe0840b56df4eb942edf8fc5</gtr:id><gtr:otherNames>Meng X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>pm_16365_25_23448204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4099CE96-79F9-4AAD-8739-214681013C3A</gtr:id><gtr:title>The S349T mutation of SQSTM1 links Keap1/Nrf2 signalling to Paget's disease of bone.</gtr:title><gtr:parentPublicationTitle>Bone</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87d1174b15c830ddb00a78aebe63c77a"><gtr:id>87d1174b15c830ddb00a78aebe63c77a</gtr:id><gtr:otherNames>Wright T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1873-2763</gtr:issn><gtr:outcomeId>pm_16365_25_23117207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36584B0C-1E9D-471E-BD19-2589774E9576</gtr:id><gtr:title>Role of the Nalp3 inflammasome in acetaminophen-induced sterile inflammation and liver injury.</gtr:title><gtr:parentPublicationTitle>Toxicology and applied pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84a7e9f036e76ff3e1ae589aeed62431"><gtr:id>84a7e9f036e76ff3e1ae589aeed62431</gtr:id><gtr:otherNames>Williams CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0041-008X</gtr:issn><gtr:outcomeId>eiDQyj8GHpW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E919B29-ACFD-40C7-B7B0-D16B740CB8FE</gtr:id><gtr:title>Human pluripotent stem cells for modeling toxicity.</gtr:title><gtr:parentPublicationTitle>Advances in pharmacology (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89cbc9f170ee302729639b71bf20ab47"><gtr:id>89cbc9f170ee302729639b71bf20ab47</gtr:id><gtr:otherNames>Sison-Young RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1054-3589</gtr:issn><gtr:outcomeId>pm_16365_25_22776643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>178DEA72-E55F-4996-9DA1-0FA7A655CA4D</gtr:id><gtr:title>Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_16365_25_22266604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D319E82F-EB68-498E-B597-70AE5FE0DE1D</gtr:id><gtr:title>Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f8b5adafdd370252c7fc6d85d8b907"><gtr:id>e8f8b5adafdd370252c7fc6d85d8b907</gtr:id><gtr:otherNames>Kia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>pm_16365_25_22703588</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B7FA67D-0FC5-4D0E-B5D8-8D31F3235129</gtr:id><gtr:title>The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>pm_16365_25_23446148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>935AC4BC-EAB8-4F5F-B729-D39B88FED411</gtr:id><gtr:title>Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f098469dc1dbb18dc75ff4bb9372c1b"><gtr:id>7f098469dc1dbb18dc75ff4bb9372c1b</gtr:id><gtr:otherNames>Goldring C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a31e8103b1ad0.55159720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>661FC60E-80F8-49EA-8B64-B99973E2E826</gtr:id><gtr:title>Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36fde6859daf9489006d8cddab8dcdbe"><gtr:id>36fde6859daf9489006d8cddab8dcdbe</gtr:id><gtr:otherNames>El-Ghaiesh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>HU6EGSLcrwG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44F9052E-7041-4612-B5C5-3507BEF4B819</gtr:id><gtr:title>Biomarkers distinguish apoptotic and necrotic cell death during hepatic ischemia/reperfusion injury in mice.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/568b1bdfe155aa165382b901542f1efb"><gtr:id>568b1bdfe155aa165382b901542f1efb</gtr:id><gtr:otherNames>Yang M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>545ce9cb15c859.14967324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A83D99F-D66D-422D-AE3D-5212C1697A19</gtr:id><gtr:title>Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity.</gtr:title><gtr:parentPublicationTitle>Molecular medicine (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1076-1551</gtr:issn><gtr:outcomeId>MQHnrwqV5EF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E74677B7-1ED9-460C-9E9A-85B24123F220</gtr:id><gtr:title>Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41b6a31628333321871b45b21a5fe2cf"><gtr:id>41b6a31628333321871b45b21a5fe2cf</gtr:id><gtr:otherNames>Aw Yeang HX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_16365_25_22311972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2BDBA66-4D70-4E5F-8A7C-A86E9CF9DBA7</gtr:id><gtr:title>Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79f8dcc26d2fd9b44ad058a8dc8172a5"><gtr:id>79f8dcc26d2fd9b44ad058a8dc8172a5</gtr:id><gtr:otherNames>Whitaker P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>NoRMvZYMu4B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BCE24F6-79F5-420A-83A1-2522C4D5CE1B</gtr:id><gtr:title>Dapsone and Nitroso Dapsone Activation of Nai?ve T-Cells from Healthy Donors.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfe0a6a92747c07b9d73c1fa5c137c1b"><gtr:id>dfe0a6a92747c07b9d73c1fa5c137c1b</gtr:id><gtr:otherNames>Alzahrani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>5a2fd8337cddc4.30173905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3FC5105-E342-42D9-88EA-945A5D404A60</gtr:id><gtr:title>Investigation of the immunogenicity of p-phenylenediamine and Bandrowski's base in the mouse.</gtr:title><gtr:parentPublicationTitle>Toxicology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cc39cb9af6b651fa3ac9be2f82e9caa"><gtr:id>7cc39cb9af6b651fa3ac9be2f82e9caa</gtr:id><gtr:otherNames>Farrell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0378-4274</gtr:issn><gtr:outcomeId>8FD4F3EE839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99E15ED8-C0F7-457E-B413-F7CB847F41F4</gtr:id><gtr:title>High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>nWo8fXtm9Yi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F503E98-9F7E-40E0-A3EA-5286E3EB86CD</gtr:id><gtr:title>?-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b23415e6bcb1811052d6abb2f91368f8"><gtr:id>b23415e6bcb1811052d6abb2f91368f8</gtr:id><gtr:otherNames>Jenkins RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>pm_16365_25_23668298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB9BFDC5-609A-4587-A5EF-623DEA42E403</gtr:id><gtr:title>In vitro diagnosis of delayed-type drug hypersensitivity: mechanistic aspects and unmet needs.</gtr:title><gtr:parentPublicationTitle>Immunology and allergy clinics of North America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d19dd5a51d1cf4ff43003c1c9e4cf808"><gtr:id>d19dd5a51d1cf4ff43003c1c9e4cf808</gtr:id><gtr:otherNames>Naisbitt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0889-8561</gtr:issn><gtr:outcomeId>pm_540e154e1544276d5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C011E9F-1611-48D1-8BB5-190A5088B6B2</gtr:id><gtr:title>Retro-orbital blood acquisition facilitates circulating microRNA measurement in zebrafish with paracetamol hepatotoxicity.</gtr:title><gtr:parentPublicationTitle>Zebrafish</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b057296e9679837049e61cda42860ace"><gtr:id>b057296e9679837049e61cda42860ace</gtr:id><gtr:otherNames>Vliegenthart AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1545-8547</gtr:issn><gtr:outcomeId>545ce9cbec1479.59042926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>295D6029-B3E7-4DBA-A164-F5B3FDBE43B7</gtr:id><gtr:title>Analysis of the role of Nrf2 in the expression of liver proteins in mice using two-dimensional gel-based proteomics.</gtr:title><gtr:parentPublicationTitle>Pharmacological reports : PR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/890daf9a1f83473e4569317fff264446"><gtr:id>890daf9a1f83473e4569317fff264446</gtr:id><gtr:otherNames>Abdullah A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1734-1140</gtr:issn><gtr:outcomeId>pm_16365_25_22814021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42BA2EED-827E-4BDF-8B82-9BCE42269469</gtr:id><gtr:title>Differential effect of covalent protein modification and glutathione depletion on the transcriptional response of Nrf2 and NF-kappaB.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/446c4dd1df36a132e7db07b5e6c537c1"><gtr:id>446c4dd1df36a132e7db07b5e6c537c1</gtr:id><gtr:otherNames>Chia AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>K1N4gwVvRzs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A73CC389-E71A-4520-B9B7-78E05CDDB30F</gtr:id><gtr:title>T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8df20b2de2b4bd06b9e98191bc54350"><gtr:id>f8df20b2de2b4bd06b9e98191bc54350</gtr:id><gtr:otherNames>Bell CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>doi_55f984984631648a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEBCD24D-3D67-4AB0-A398-B0B96A4DC729</gtr:id><gtr:title>A multi-factorial analysis of response to warfarin in a UK prospective cohort.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7688f27d44898d99f0ac44466d5f7660"><gtr:id>7688f27d44898d99f0ac44466d5f7660</gtr:id><gtr:otherNames>Bourgeois S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>5694dcd5f02498.47339527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6475F2B8-BB72-4BE1-8118-153B61294837</gtr:id><gtr:title>OP0235 Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56717a6a0cf5d1.33653938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F02790B-D699-4AAB-8749-30060FBF8963</gtr:id><gtr:title>Role of Nrf2 in protection against acute kidney injury.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca30cc0ad8c0f95e3c2b7f9bad321798"><gtr:id>ca30cc0ad8c0f95e3c2b7f9bad321798</gtr:id><gtr:otherNames>Shelton LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>pm_16365_25_23783243</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79C40C42-2827-4849-A844-F91E625572D7</gtr:id><gtr:title>Roles of Nrf2 in drug and chemical toxicity</gtr:title><gtr:parentPublicationTitle>Current Opinion in Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bde731ec668d4a9d960163b07955ad2d"><gtr:id>bde731ec668d4a9d960163b07955ad2d</gtr:id><gtr:otherNames>Clarke J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d340d379ed1.87738280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB7032C0-2125-4412-B5A7-8A79A629209E</gtr:id><gtr:title>Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18b81367b9cdf73b016574a36a182dee"><gtr:id>18b81367b9cdf73b016574a36a182dee</gtr:id><gtr:otherNames>Usui T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>5a995f1adbbaf1.14836959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEBFEE10-255E-4DCC-885F-9C5414EB1B3F</gtr:id><gtr:title>Challenges and approaches for the development of safer immunomodulatory biologics.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a0b901e99029dbf934cd6c0f3f82167"><gtr:id>6a0b901e99029dbf934cd6c0f3f82167</gtr:id><gtr:otherNames>Sathish JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>pm_16365_25_23535934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E012D482-B592-4D32-BB38-5B11D220A97E</gtr:id><gtr:title>IL-8 release from human neutrophils cultured with pro-haptenic chemical sensitizers.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/856f961ca119cd11b25b777dc1d64f51"><gtr:id>856f961ca119cd11b25b777dc1d64f51</gtr:id><gtr:otherNames>Kiorpelidou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>pm_16365_25_22946548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BB497A8-77CA-4A59-A905-0CE1F062D312</gtr:id><gtr:title>Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries.</gtr:title><gtr:parentPublicationTitle>Drug metabolism and disposition: the biological fate of chemicals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d16f1cc27ff7a3ed67df666f3d1c745"><gtr:id>4d16f1cc27ff7a3ed67df666f3d1c745</gtr:id><gtr:otherNames>Srivastava A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0090-9556</gtr:issn><gtr:outcomeId>qZywR8oqcja</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>445869FC-3CD6-4EC3-A79A-6733F9B7874D</gtr:id><gtr:title>Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.</gtr:title><gtr:parentPublicationTitle>mAbs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f2460e22e02f843ac20e5dbf3ea66b1"><gtr:id>9f2460e22e02f843ac20e5dbf3ea66b1</gtr:id><gtr:otherNames>Thaventhiran T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1942-0862</gtr:issn><gtr:outcomeId>doi_55f9849846526189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E533B63B-CA66-422F-8740-91B605BA024D</gtr:id><gtr:title>Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/680299749fee66592d9b71eb2e0e6698"><gtr:id>680299749fee66592d9b71eb2e0e6698</gtr:id><gtr:otherNames>Elliott VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>pm_16365_25_22480236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25C051E5-688A-43F7-B96F-7D40B4CAABB7</gtr:id><gtr:title>Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36c3f85de3f9f88c27d2230e55032c0c"><gtr:id>36c3f85de3f9f88c27d2230e55032c0c</gtr:id><gtr:otherNames>Elsheikh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_16365_25_21354601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A87AE90B-6A9D-4DD2-A2E6-4CA7B046CCDE</gtr:id><gtr:title>Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c9b31e02c2c5e3fd2ab8ca180b93030"><gtr:id>1c9b31e02c2c5e3fd2ab8ca180b93030</gtr:id><gtr:otherNames>Walsh J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn><gtr:outcomeId>545ce9cb5f7308.99534196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F99EA618-944D-44C9-A3C2-AABE2C0E0415</gtr:id><gtr:title>Serum microRNA biomarkers for drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebe471943ec9fecbf4f5c3cf016c41d9"><gtr:id>ebe471943ec9fecbf4f5c3cf016c41d9</gtr:id><gtr:otherNames>Starkey Lewis PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_16365_25_22828715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E145D64-0EEC-48C1-BA50-75EEA604FB8A</gtr:id><gtr:title>Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15d401f5b5bddc3251738d50627959a6"><gtr:id>15d401f5b5bddc3251738d50627959a6</gtr:id><gtr:otherNames>Pointon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>pm_16365_25_23315586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C61F8E0-7553-43C8-B88B-D19A2273399C</gtr:id><gtr:title>Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca30cc0ad8c0f95e3c2b7f9bad321798"><gtr:id>ca30cc0ad8c0f95e3c2b7f9bad321798</gtr:id><gtr:otherNames>Shelton LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>56d565153ef442.09172817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F84ACF9C-0730-4F2A-A1A7-A8AF5D964E6D</gtr:id><gtr:title>The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9d7587f4ad96c426ef860b78d68e47b"><gtr:id>b9d7587f4ad96c426ef860b78d68e47b</gtr:id><gtr:otherNames>Mercer AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>hJWJDf75KgM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DA90783-5F61-4658-9A8B-50744E96AB08</gtr:id><gtr:title>Circulating Kidney Injury Molecule 1 Predicts Prognosis and Poor Outcome in Patients With Acetaminophen-Induced Liver Injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>553dfc00b536a9.25772516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>675ED33B-6FC0-475E-BAF5-21074F1A03C8</gtr:id><gtr:title>In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5866bff6b7be8772b0bc13c9117fba67"><gtr:id>5866bff6b7be8772b0bc13c9117fba67</gtr:id><gtr:otherNames>Alfirevic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>pm_16365_25_22732016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD33DFBA-43B7-49A6-A807-9308497D198F</gtr:id><gtr:title>Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c047db003343a556ea9b871f846ffaba"><gtr:id>c047db003343a556ea9b871f846ffaba</gtr:id><gtr:otherNames>Lister A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>DS3D1kswoMU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D54F159C-FAF5-4161-8CA8-B7D438E572A7</gtr:id><gtr:title>Characterization of Peroxidases Expressed in Human Antigen Presenting Cells and Analysis of the Covalent Binding of Nitroso Sulfamethoxazole to Myeloperoxidase.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3bfa3b7807d59b84b48dfd2a1228e74"><gtr:id>e3bfa3b7807d59b84b48dfd2a1228e74</gtr:id><gtr:otherNames>Ogese MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>5675de0dc04d7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF30C58F-3AF2-4FB3-AF5F-5ADD1E156E4E</gtr:id><gtr:title>Differential expression of cell surface markers in response to 2,4-dinitrofluorobenzene in RAW 264.7 and primary immune cells.</gtr:title><gtr:parentPublicationTitle>BMB reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86910a5522b1840d8561cae1606156ed"><gtr:id>86910a5522b1840d8561cae1606156ed</gtr:id><gtr:otherNames>Kim D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1976-6696</gtr:issn><gtr:outcomeId>pm_16365_25_23010176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51B8A253-B12D-4F87-8DDD-D54248924353</gtr:id><gtr:title>Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22a484d9263ec3af12b8fffb767bf0a5"><gtr:id>22a484d9263ec3af12b8fffb767bf0a5</gtr:id><gtr:otherNames>Monshi MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_16365_25_22987284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B809002-3034-437A-A6CF-531DA9782952</gtr:id><gtr:title>Abacavir forms novel cross-linking abacavir protein adducts in patients.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b7b1dadfe0840b56df4eb942edf8fc5"><gtr:id>9b7b1dadfe0840b56df4eb942edf8fc5</gtr:id><gtr:otherNames>Meng X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>pm_540e154e15424e405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE13C975-054A-4E54-B44E-5AE758CE540B</gtr:id><gtr:title>Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34ae85010ef2635e8fbe3328a3928243"><gtr:id>34ae85010ef2635e8fbe3328a3928243</gtr:id><gtr:otherNames>Wong MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>585d52c62f6180.83177497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBC3A5B7-62BB-4099-8340-5E9095562EE2</gtr:id><gtr:title>Oxidative bioactivation of abacavir in subcellular fractions of human antigen presenting cells.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8df20b2de2b4bd06b9e98191bc54350"><gtr:id>f8df20b2de2b4bd06b9e98191bc54350</gtr:id><gtr:otherNames>Bell CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>doi_55f98498462814df</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>706C9193-6995-4EEF-8794-425942E93072</gtr:id><gtr:title>Network analysis of primary hepatocyte dedifferentiation using a shotgun proteomics approach.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fcf6319aaaa051e71570ab1a5fbb0d4"><gtr:id>7fcf6319aaaa051e71570ab1a5fbb0d4</gtr:id><gtr:otherNames>Rowe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>jDYsEDLBF1r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>324C0216-2A6A-414C-B17B-ABE26E1371EE</gtr:id><gtr:title>Statin regulated ERK5 stimulates tight junction formation and reduces permeability in human cardiac endothelial cells.</gtr:title><gtr:parentPublicationTitle>Journal of cellular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f33afcd1d7002fa259a663164003992d"><gtr:id>f33afcd1d7002fa259a663164003992d</gtr:id><gtr:otherNames>Wilkinson EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0021-9541</gtr:issn><gtr:outcomeId>5a2fd3712d1328.83659039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C504FDA8-4B44-44D6-8484-C63B6247BBBC</gtr:id><gtr:title>Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36fde6859daf9489006d8cddab8dcdbe"><gtr:id>36fde6859daf9489006d8cddab8dcdbe</gtr:id><gtr:otherNames>El-Ghaiesh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>pm_16365_25_22371438</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2B74DED-8581-4E45-B572-90791F132A0C</gtr:id><gtr:title>Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9938df0bfdfb500f731f17be25c08d8"><gtr:id>f9938df0bfdfb500f731f17be25c08d8</gtr:id><gtr:otherNames>Sabbisetti VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5460edd7de41d5.67820069</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700654</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>